Identification of Post-translationally Modified MHC Class I-Associated Peptides as Potential Cancer Immunotherapeutic Targets.

ABSTRACT: Over the past 3 decades, the Hunt laboratory has developed advancements in mass spectrometry-based technologies to enable the identification of peptides bound to major histocompatibility complex (MHC) molecules. The MHC class I processing pathway is responsible for presenting these peptides to circulating cytotoxic T cells, allowing them to recognize and eliminate malignant cells, many of which have aberrant signaling. Professor Hunt hypothesized that due to the dysregulation in phosphorylation in cancer that abnormal phosphopeptides could be presented by this pathway, and went on to demonstrate that this was, in fact, the case. Thereafter, the laboratory continued to sequence MHC-associated phosphopeptides and contributed several improved methods for their enrichment, detection, and seque

SUBMITTER: Mahoney KE 

PROVIDER: S-EPMC12362676 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature